Kevzara (sarilumab) vs Truxima (rituximab)
Kevzara (sarilumab) vs Truxima (rituximab)
Kevzara (sarilumab) is an interleukin-6 (IL-6) receptor antagonist indicated for the treatment of adults with moderate to severe rheumatoid arthritis (RA) who have had an inadequate response to one or more disease-modifying antirheumatic drugs (DMARDs). Truxima (rituximab), a biosimilar to Rituxan, is a CD20-directed cytolytic antibody used for treating several conditions, including RA, non-Hodgkin's lymphoma, and chronic lymphocytic leukemia, often after other treatments have failed. While both medications can be used for RA, they operate through different mechanisms and may be chosen based on a patient's specific medical history, previous treatment responses, and the presence of any comorbid conditions. It is critical for a patient to consult with their healthcare provider to determine which medication is most appropriate for their individual condition.
Difference between Kevzara and Truxima
| Metric | Kevzara (sarilumab) | Truxima (rituximab) |
|---|---|---|
| Generic name | Sarilumab | Rituximab |
| Indications | Moderate to severe rheumatoid arthritis | Non-Hodgkin's lymphoma, Chronic lymphocytic leukemia, Rheumatoid arthritis, Granulomatosis with polyangiitis, Microscopic polyangiitis |
| Mechanism of action | Interleukin-6 receptor antagonist | CD20-directed cytolytic antibody |
| Brand names | Kevzara | Truxima, Rituxan |
| Administrative route | Subcutaneous injection | Intravenous infusion |
| Side effects | Upper respiratory infections, Urinary tract infections, Injection site reactions, Increased liver enzymes, Neutropenia | Infusion reactions, Infections, Lymphopenia, Anemia, Neutropenia |
| Contraindications | Active, severe infection | Hepatitis B reactivation, Severe infections, Severe cardiac disease |
| Drug class | Immunosuppressive drug, Disease-modifying antirheumatic drug (DMARD) | Monoclonal antibody, Antineoplastic agent, Immunomodulator |
| Manufacturer | Sanofi and Regeneron Pharmaceuticals | Celltrion Healthcare, Teva Pharmaceuticals, Genentech (a member of the Roche Group) |
Efficacy
Kevzara (Sarilumab) for Rheumatoid Arthritis
Kevzara, with the active ingredient sarilumab, is a human monoclonal antibody designed for the treatment of adults with moderate to severe rheumatoid arthritis (RA) who have had an inadequate response or intolerance to one or more disease-modifying antirheumatic drugs (DMARDs). Sarilumab works by blocking the interleukin-6 (IL-6) receptor, which plays a key role in the inflammatory process of RA. Clinical trials have demonstrated that Kevzara, particularly when combined with methotrexate, can reduce the signs and symptoms of RA, improve physical function, and inhibit the progression of joint damage.
The efficacy of Kevzara was established through several pivotal phase III clinical trials, including the MOBILITY and TARGET studies. These studies showed that patients treated with Kevzara experienced statistically significant improvements in both the American College of Rheumatology criteria (ACR20) response rates and Health Assessment Questionnaire-Disability Index (HAQ-DI) scores compared to placebo. Additionally, radiographic progression of joint damage was significantly slowed in patients receiving Kevzara in combination with methotrexate.
Truxima (Rituximab) for Rheumatoid Arthritis
Truxima, a biosimilar to Rituxan (rituximab), is another medication used in the treatment of rheumatoid arthritis, particularly in patients who have had an inadequate response to one or more tumor necrosis factor (TNF) antagonist therapies. Rituximab is a chimeric monoclonal antibody that targets the CD20 antigen on B lymphocytes, cells that are implicated in the pathogenesis of RA. The administration of Truxima leads to the depletion of these B cells, which is thought to help reduce the inflammation and joint damage associated with RA.
The efficacy of rituximab for the treatment of RA has been demonstrated in several clinical trials, including the REFLEX and SERENE studies. These studies have shown that rituximab, in combination with methotrexate, can significantly reduce symptoms of RA as measured by ACR20 response rates, and improve physical function as assessed by HAQ-DI scores. Furthermore, rituximab has been shown to inhibit the progression of structural damage in patients with RA, as evidenced by radiographic analyses. Truxima, as a biosimilar, is expected to produce similar efficacy outcomes to those observed with the reference product, Rituxan.
Regulatory Agency Approvals
Kevzara
-
European Medical Agency (EMA), European Union
-
Food and Drug Administration (FDA), USA
-
Health Canada
-
Therapeutic Goods Administration (TGA), Australia
Truxima
-
European Medical Agency (EMA), European Union
-
Food and Drug Administration (FDA), USA
-
Health Canada
-
Therapeutic Goods Administration (TGA), Australia
-
Medsafe (NZ)
Access Kevzara or Truxima today
If Kevzara or Truxima are not approved or available in your country (e.g. due to supply issues), you can access them via Everyone.org.
How it works
Make an enquiry
Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.
Make an enquiry
Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.
Breeze through the paperwork
We'll guide you through the required documents for importing unapproved medicine, ensuring you have all the necessary information.
Get a personalized quote
We’ll prepare a quote for you, including medicine costs and any shipping, administrative, or import fees that may apply.
Receive your medicine
Accept the quote and we’ll handle the rest - sourcing and safely delivering your medicine.
Some text on this page has been automatically generated. Speak to your physician before you start a new treatment or medication.
Let's talk
If you have any questions, call us or send us a message through WhatsApp or email:
Contact us